TrialBMC cancer2008

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

A del Giglio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.